Asthma

Phase 3 data from KALOS and LOGOS trial support triple therapy in uncontrolled asthma, for both adolescents and adults.

New phase 3 data show single-inhaler triple therapy boosts FEV₁ and cuts severe asthma attacks for patients uncontrolled on ICS–LABA.

Approval of the novel long-acting mAb was based on the phase 3 SWIFT-1 and SWIFT-2 trials, which showed steep reductions in annualized asthma exacerbations requiring ED or inpatient care.

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.

WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.

A family medicine physician details how to differentiate upper airway cough syndrome from asthma and GERD using clinical history and associated symptoms.

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

Large US cohort study finds COVID-19 infection increases short-term risk of asthma, allergic rhinitis, and chronic rhinosinusitis, while vaccination lowers these risks.

Your daily dose of the clinical news you may have missed.

A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.